What happened to InVivo Therapeutics Holdings Corp (Ivo) stock?
The InVivo Therapeutics Holdings Corp. stock price gained 1.92% on the last trading day (Wednesday, 19th Jan 2022), rising from $0.50 to $0.51. During the day the stock fluctuated 5.05% from a day low at $0.50 to a day high of $0.52. The price has been going up and down for this period, and there has been a -5.44% loss for the last 2 weeks.
What is the price of nviv stock?
One share of NVIV stock can currently be purchased for approximately $0.50. How much money does InVivo Therapeutics make? InVivo Therapeutics has a market capitalization of $17.26 million.
How much does InVivo Therapeutics make a year?
Invivo Therapeutics has a market capitalization of $5.96 million. The biotechnology company earns $-23,420,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe.View Additional Information About Invivo Therapeutics.
What is InVivo’s technology?
InVivo’s proprietary and investigational Neuro-Spinal Scaffold, based on technology licensed from Robert S. Langer’s lab at Massachusetts Institute of Technology, is in pivotal clinical studies for acute spinal cord injury. The company is headquartered in Cambridge, MA.
Is InVivo a good stock to buy?
The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 937.50, with a high estimate of 937.50 and a low estimate of 937.50. The median estimate represents a +20,236.23% increase from the last price of 4.61.
What happened to InVivo Therapeutics?
Publisher & Founder. Shares of InVivo Therapeutics $NVIV tanked this morning after the Cambridge, MA-based biotech said it halted enrollment in its lead INSPIRE study after the third patient treated with its spinal cord implant died. InVivo shares plunged more than 30%.
What does InVivo Therapeutics do?
About us. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.
How has InVivo Therapeutics' stock price performed in 2022?
InVivo Therapeutics' stock was trading at $11.4025 on January 1st, 2022. Since then, NVIV stock has decreased by 59.7% and is now trading at $4.60....
When is InVivo Therapeutics' next earnings date?
InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for I...
How were InVivo Therapeutics' earnings last quarter?
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its earnings results on Tuesday, May, 10th. The biotechnology company reported ($1.94) EPS...
When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?
InVivo Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27t...
Who are InVivo Therapeutics' key executives?
InVivo Therapeutics' management team includes the following people: Dr. Richard M. Toselli , Pres, CEO, Chief Medical Officer & Director (Age 64...
Who are some of InVivo Therapeutics' key competitors?
Some companies that are related to InVivo Therapeutics include NeuroMetrix (NURO) , Bluejay Diagnostics (BJDX) , PetVivo (PETV) , Nephros (NEPH...
What other stocks do shareholders of InVivo Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Scie...
What is InVivo Therapeutics' stock symbol?
InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
Who are InVivo Therapeutics' major shareholders?
InVivo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (...
When will Invivo Therapeutics stock split?
What is the official website of Invivo Therapeutics?
InVivo Therapeutics's stock reverse split before market open on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.
What is Invivo Therapeutics?
The official website for InVivo Therapeutics is www.invivotherapeutics.com.
What is the NVIV symbol?
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.
When is the 1-30 reverse split?
InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
Does Invivo Therapeutics pay dividends?
The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.
News & Analysis: InVivo Therapeutics Holdings
InVivo Therapeutics does not currently pay a dividend.
Environmental, Social, and Governance Rating
There is no available coverage of InVivo Therapeutics Holdings at this time.
What is Invivo Therapeutics?
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Is InVivo Therapeutics Holdings Corp. stock A Buy?
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Bioengineered Neural Trails injection program for the treatment of chronic SCI. The company was founded in ... Read more
What is Invitro's net income for 2021?
InVivo Therapeutics Holdings Corp. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
What is IRP in Invitro?
PLACENTIA, CA / ACCESSWIRE / February 10, 2021 / InVitro International (OTCPINK:IVRO) is pleased to announce net income of $67,663 in its first fiscal quarter of 2021, ending December 31st, 2020. This represents a 40% increase compared to net income of $48,177 from prior year's first quarter.
